$157-210k
OTE
Listed range is Total Cash Compensation (including base pay, variable pay, commission, bonuses, etc.). Offers stock options
AI-powered heart disease diagnostics
Be an early applicant
AI-powered heart disease diagnostics
101-200 employees
Be an early applicant
$157-210k
OTE
Listed range is Total Cash Compensation (including base pay, variable pay, commission, bonuses, etc.). Offers stock options
101-200 employees
Cleerly's mission is to create digital care pathways to prevent heart attacks.
Jump to section
Cleerly's mission is to create digital care pathways to prevent heart attacks.
For all the advancements made in modern medicine, it’s remarkable that cardiovascular diseases still cause around 18 million deaths every year. The WHO estimates that these diseases account for, or contribute to, around 30% of deaths each year.
Traditional heart disease evaluation methods, such as a coronary angiogram, can be invasive - a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels.
Though serious complications from the procedure are rare, they potentially include injury to the artery, an allergic reaction or kidney damage from the dye, as well as heart attack or stroke. This is a problem that Cleerly is trying to solve by measuring this plaque through AI-powered imaging which analyzes non-invasive coronary CT scans.
The company was founded by the respected cardiologist and radiologist James Min in 2017 and spent its early years developing and refining its tech. However, it recently secured major financial backing, which coincides with CTA imaging’s growing status as a priority measure for patients with suspected heart problems. This is set to propel Cleerly into a period of rapid growth as it looks to keep refining its software to attract and keep new customers in the healthcare industry.
Kirsty
Company Specialist at Welcome to the Jungle
Dec 2024
$106m
SERIES C
Jul 2022
$223m
SERIES C
This company has top investors
Dr. James Min
(CEO)Former Professor of Radiology and Medicine in Cardiology at Weill Cornell Medical College and the New York-Presbyterian Hospital. Former Director of the Dalio Institute of Cardiovascular Imaging.